Key statistics
On Thursday, Immuneering Corp (IMRX:NMQ) closed at 2.11, 111.00% above the 52 week low of 1.00 set on Aug 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.03 |
---|---|
High | 2.23 |
Low | 2.03 |
Bid | 2.11 |
Offer | 2.18 |
Previous close | 2.04 |
Average volume | 426.24k |
---|---|
Shares outstanding | 29.65m |
Free float | 21.02m |
P/E (TTM) | -- |
Market cap | 62.57m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
- Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
- Immuneering to Present at the Jefferies Global Healthcare Conference
- Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Recognizes Melanoma Awareness Month
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
More ▼